A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma

Abstract

Background: Omaveloxolone (Omav) reduces production of reactive oxygen and nitrogen species by myeloid derived suppressor cells (MDSCs) and restores immune surveillance in preclinical cancer models. Administration of Omav with checkpoint inhibitors (CI) may enhance the anti-Tumor immune response of immunotherapies. A Phase 1b/2 study was designed to evaluate the safety and efficacy of Omav in combination with ipilimumab (Ipi) or nivolumab (Nivo) for treatment of patients with unresectable or metastatic melanoma. Data from the ongoing Phase 1b study are reported. Method(s): Patients with or without prior exposure to CI, and with >5% of tumor cells from a screening biopsy positive for inducible nitric oxide synthase (iNOS) were enrolled. Serial biopsies were also collected at Weeks 2 and 13. Omav monotherapy (5, 10, 20, 100, or 150 mg PO QD) was dosed continuously starting one week prior to CI initiation (Ipi x 4 doses or Nivo q 2 weeks). Primary objectives were safety, MTD, and ORR measured via RECIST v1.1. Result(s): At data cutoff, 39 patients were enrolled (Omav +Ipi: n=12; Omav + Nivo: n=27) with median treatment duration of 13 weeks. Of 30 patients with evaluable tumor restaging, 7/30 (23%) of patients were CI-naive, while 23/30 (77%) of patients were refractory to prior CI therapy. The ORR (confirmed + unconfirmed) observed in all evaluable patients was 8/30 (27%, 6 partial response (PR) and 2 complete response (CR)) and 4/7 (57%) in CI-naive patients, including 1 CR. 3/18 (17%) patients treated with Omav + Nivo who were refractory to prior CI therapies had objective responses including 1 CR. Omav was associated with decreases in tumor iNOS, PD-L1, and IDO-1 expression. The MTD for Omav has not been established since no dose-limiting toxicities were observed. No serious AEs considered related to Omav have been reported to date. Commonly reported treatment-related adverse events included fatigue, nausea, pruritus, transaminase increases and decreased appetite. Conclusion(s): Omav was well tolerated at doses up to 150 mg in combination with CI and initial efficacy data suggest that Omav may overcome CI resistance. The Phase 2 portion of the trial will study the effects of Omav with Nivo in patients refractory to prior anti-PD-1/PD-L1 therapies. Clinical trial identification: NCT02259231 Legal entity responsible for the study: Reata Pharmaceuticals Funding: Reata Pharmaceuticals Disclosure: S.P. Patel: Research funding (paid to institution): BMS, Deciphera, Novartis, Reata. Advisory board: Amgen, Castle Biosciences, Genentech, Incyte, OncoSec. DSMB: Immunocore, Reata. Non-promotional speaker's bureau for: BMS, Merck. F.S. Hodi. Consultant for Merck, Bristol-Myers Squibb, EMD Serono, Novartis, Genentech, Amgen, Celldex. D. Gabrilovich: Research grant from Reata. M. Chin, A. Goldsberry, J. Hurt: Employee of Reata Pharmaceuticals. G. Gibney: Consultant for Genentech, Novartis, Incyte. Speaker's bureau for Genentech, Merck. J. Markowitz: Consultant to Idera and Newlink Genetics. E. Whitman: Speaker's bureau and Advisory board for BMS. C. Meyer: Employeer of Reata Pharmaceuticals. A. Salama: Research funding (paid to institution): BMS, Celldex, Genentech, Merck, Immunocore. Advisory board: Merck. Speaker's bureau: BMS. Spouse: Research funding/ national PI- AbbVie. All other authors have declared no conflicts of interest.